INNOVATE Corp. (VATE) | The Buildout — AI Infrastructure
The Verdict
INNOVATE Corp. is a diversified holding company whose AI-infrastructure role sits inside DBM Global, a fully integrated structural steel fabricator and erector. DBMG fabricates and erects steel for data centers, chipmaker facilities, and other technology-related projects, with value in fabrication capacity, erection capability, and digital engineering. After the quarter ended, INNOVATE agreed to sell DBM Global to IES Holdings, which would remove the AI-linked segment from the structure.
| Market Cap | — |
| Revenue (TTM) | $1.3B |
| Revenue Growth | +25.4% |
| EBITDA Margin (TTM) | 5.1% |
| Net Debt | $631M |
| Earnings Beats | 6 of 6 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Infrastructure revenue was $357.9 million in Q1 2026, up 35.1% y/y and roughly 98% of consolidated revenue.
- Adjusted backlog held at $1.8 billion while revenue grew; Infrastructure remaining performance obligations were $1,585.6 million, with $1,141.1 million due within one year.
- Infrastructure gross margin compression narrowed to about 140 bps y/y in Q1 2026, from about 510 bps in Q3 2025.
- Management says the majority of platform work is associated infrastructure, data centers, and advanced manufacturing.
- Post-quarter agreement to sell DBM Global to IES Holdings for approximately $650 million could address parent capital constraints if closed.
What We’re Watching
- DBM sale closing timing, cash/stock split, and use of proceeds are not disclosed.
- Two unnamed Infrastructure customers were 31.0% and 13.9% of Q1 2026 revenue, versus below 10% each in Q1 2025.
- R2 revenue fell 48.4% y/y to $1.6 million while its system backlog grew to about 160 systems; R2 is seeking external capital through 2026.
- The Q1 2026 10-Q includes a going concern qualification.
The Infrastructure core strengthened in Q1 2026, and the signed DBM sale is the major structural step management hinted at. But that transaction would remove the segment that supplies nearly all consolidated revenue and adjusted EBITDA, leaving a much smaller Life Sciences/Spectrum/corporate entity with a going concern qualification and only $2.5 million of parent cash. The key open question is what the remaining company and capital structure look like after the DBM sale closes.
Earnings Beat
Consolidated revenue was $364.8 million in Q1 2026, up 33% y/y, with gross margin of 13.5%. Management-reported adjusted EBITDA was $19.7 million, up from $7.2 million. Infrastructure revenue was $357.9 million, up 35.1%, while Life Sciences revenue fell 48.4% to $1.6 million and Spectrum revenue declined to $5.3 million.
| Metric | Q1 FY2026 | Q4 FY2025 | Q1 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $365M | $383M | $274M | +33.0% |
| Gross margin | 13.5% | 14.2% | 15.0% | -150bps |
| EBITDA | $18M | $23M | $12M | +50.4% |
| EPS | $-1.26 | $-0.56 | $-1.87 | −32.5% |
| Adjusted backlog | $1.8B | $1.8B | n/a | — |
We see a lot of capital is moving into physical infrastructure for computing in the United States. We are specifically seeing opportunities in technology-related construction markets and are concentrated around AI infrastructure, energy systems, advanced manufacturing and digital connectivity.— Paul Voigt, Interim CEO, May 14, 2026
Management tone: Management's prepared remarks were optimistic on Infrastructure demand and on building backlog for 2027, and the CEO hinted at 'positive news' ahead. On strategic alternatives, language shifted from an explicit Jefferies-led DBM sale process to 'working with lenders on strategic alternatives.' The call again had no analyst questions.
Management Guidance
No quantitative guidance was issued. Management's forward statements were directional: Infrastructure visibility extending, focus shifting to disciplined capacity-aligned growth and early success in building backlog for 2027; and Spectrum discussing new market launches in H2 2026. Disclosed MediBeacon regulatory milestones include CE mark under EU MDR, FDA IDE approvals for multiple studies, and China NMPA approval for Lumitrace injection received October 21, 2025.
Trajectory
Consolidated revenue rose from $274.2 million in Q1 2025 to $364.8 million in Q1 2026, a 33% y/y increase. Revenue stepped from $242 million in Q2 2025 to $347 million in Q3 2025 and $383 million in Q4 2025, then declined 4.7% sequentially to $364.8 million in Q1 2026 on project timing. Gross margin was 13.5% overall, while Infrastructure gross margin compressed about 140 bps y/y to 14.2%; the compression narrowed sharply from about 510 bps in Q3 2025.
The Model
The model projects FY+1 revenue of $1,500 million and EBITDA of $87 million, implying a 5.8% EBITDA margin. For FY+2, the model projects revenue of $1,590 million and EBITDA of $102 million, a 6.4% margin. The near-term anchor is the $1.8 billion adjusted backlog and $1,141.1 million in Infrastructure performance obligations due within one year; the FY+2 step assumes continued capacity-aligned growth and backlog for 2027.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $1.2B | $1.5B | $1.6B |
| YoY Growth | — | +20.4% | +6.0% |
| EBITDA | $62M | $87M | $102M |
| EBITDA Margin | 5.0% | 5.8% | 6.4% |
Projections are the median of 5 independent model runs. The model’s revenue sits 18.0% below analyst consensus.
No quantitative guidance was issued. Management's forward statements were directional: Infrastructure visibility extending, focus shifting to disciplined capacity-aligned growth and early success in building backlog for 2027; and Spectrum discussing new market launches in H2 2026. Disclosed MediBeacon regulatory milestones include CE mark under EU MDR, FDA IDE approvals for multiple studies, and China NMPA approval for Lumitrace injection received October 21, 2025.
What Could Go Right — and Wrong
- Infrastructure converts its $1.8 billion adjusted backlog and $1,141.1 million within-one-year RPO into sustained high-revenue quarters.
- The DBM Global sale to IES Holdings closes, bringing cash and IES common stock into the parent and reducing near-dated debt pressure.
- Infrastructure gross margin compression continues to narrow from the 140 bps y/y level, helped by management's capacity-aligned selectivity.
- R2's approximately 160-system backlog converts once external capital is secured.
- Spectrum completes H2 2026 mobile-carrier market launches and converts LPTV/Class A applications into FCC grants.
- The DBM sale fails or is renegotiated, leaving the parent with $699 million of debt, $2.5 million of corporate cash, and unresolved covenant pressure.
- Two unnamed Infrastructure customers at 31.0% and 13.9% of Q1 2026 revenue delay or cancel work.
- R2 cannot raise external capital or convert its 160-system backlog; North American Glacial unit sales keep falling.
- Steel and tariff cost inflation keeps DBMG gross margin compressed, given 67.2% of steel value comes from two suppliers.
- Spectrum remains P&L-negative or near break-even; carrier launches do not reach commercial scale.
Looking Ahead
The next 12 months are defined by portfolio restructuring. The DBM Global sale to IES Holdings is signed but closing timing is not disclosed; the Broadcasting refinancing and partial sale are also in motion. The Q1 2026 10-Q includes a going concern qualification. Spectrum carrier launches and R2 financing are expected in the second half or through 2026. Q2 2026 results were filed but not covered in the source material.
- Not disclosedDBM Global sale closing — Closing timing is not stated in the source material.
- H2 2026Spectrum carrier launch discussions — Mobile carrier market launches under discussion following completed trials.
- Through 2026R2 external capital — R2 is seeking external capital to continue progress through 2026.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | $1.3B | +12.5% |
| Gross Margin | 19.0% | 15.3% | 14.6% | 370bps |
| EBITDA | $73M | $62M | $419M | -15.0% |
| EBITDA Margin | 6.6% | 5.0% | 5.1% | 161bps |
| Net Income | −$35M | −$61M | −$53M | -75.1% |
| Free Cash Flow | −$10M | $120M | $541M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)14.6%
- EBITDA Margin (TTM)5.1%
- Net Margin (TTM)-4.0%
- ROIC7.9%
- FCF Conversion257.0%
- SBC / Revenue0.2%
The Company
INNOVATE Corp. is a diversified holding company with three operating reportable segments: Infrastructure (DBM Global Inc.), Life Sciences (Pansend/R2 Technologies/MediBeacon/Genovel), and Spectrum (HC2 Broadcasting Holdings Inc.). DBM Global is a fully integrated construction company whose core businesses—Schuff Steel, Banker Steel, and GrayWolf Industrial—provide structural steel fabrication and erection, heavy steel plate fabrication, heavy equipment installation, maintenance and shutdown services, pressure vessels, strainers, filters, separators, and digital engineering.
DBMG is headquartered in Phoenix, Arizona. Schuff Steel operates six fabrication shops in Arizona, California, Kansas, and Utah; Banker Steel operates three shops in New Jersey and Virginia with maximum annual capacity of about 139,000 tons. INNOVATE's corporate headquarters is in New York, New York; R2 Technologies is in Dublin, California, and uses a single third-party contract manufacturer in Sunnyvale, California.
Business Segments
Competitive Landscape
The supplied source extracts do not include a detailed fabricator-level competitor section. Source 3's computed criticality assessment states that if VATE's Infrastructure segment could not deliver, customers would shift to other fabricators like SME Steel or W&W/AFCO, with no systemic slowdown.
- SME SteelSource 3 computed criticality assessment names SME Steel as an alternative fabricator.
- W&W/AFCOSource 3 computed criticality assessment names W&W/AFCO as an alternative fabricator.
Supply Chain
DBMG sits downstream of steel producers and upstream of general contractors, owners, and data-center operators. It is a fabricator/erector, not a commodity steel producer.